Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)
Moreno, Mía.; Mol, B.M.; von Mensdorff-Pouilly, S.; Verheijen, Ré.H.M.; von Blomberg, B.Mary.E.; van den Eertwegh, A.J.M.; Scheper, R.J.; Bontkes, H.J.
Cancer Letters 272(1): 70-76
huHMFG-1 (AS1402) is a humanised IgG1 against MUC1, which exerts tumour cell killing through antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells. Here, we explored the capacity of invariant NKT (iNKT) cells, which are known to activate NK cells, and toll-like receptor (TLR) ligands which activate both iNKT and NK cells, to enhance huHMFG-1-ADCC. Addition of iNKT cells, as well as TLR2/6, 7, 8 and 9 agonists to PBMC improved the efficacy of huHMFG-1.